Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
106M
-
Number of holders
-
76
-
Total 13F shares, excl. options
-
28.2M
-
Shares change
-
+3.4M
-
Total reported value, excl. options
-
$327M
-
Value change
-
+$27.4M
-
Number of buys
-
49
-
Number of sells
-
-34
-
Price
-
$11.57
Significant Holders of Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) as of Q2 2022
103 filings reported holding VRDN - Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value as of Q2 2022.
Viridian Therapeutics, Inc.\DE - Common Stock, $0.01 par value (VRDN) has 76 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.2M shares
of 106M outstanding shares and own 26.69% of the company stock.
Largest 10 shareholders include VR Adviser, LLC (1.85M shares), BVF INC/IL (1.74M shares), COMMODORE CAPITAL LP (1.64M shares), BlackRock Inc. (1.42M shares), VANGUARD GROUP INC (1.41M shares), TCG Crossover Management, LLC (1.31M shares), Paradigm Biocapital Advisors LP (1.31M shares), Vivo Capital, LLC (1.3M shares), Deep Track Capital, LP (1.17M shares), and MILLENNIUM MANAGEMENT LLC (1.13M shares).
This table shows the top 76 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.